Collegium Pharmaceutical, Inc. (COLL)

NASDAQ:
COLL
| Latest update: Apr 15, 2026, 5:21 PM

Stock events for Collegium Pharmaceutical, Inc. (COLL)

Several events impacted Collegium Pharmaceutical, Inc.'s stock price over the past six months. Collegium reported strong third-quarter 2025 financial results, leading to raised full-year 2025 guidance. An analysis suggested Collegium was undervalued, with potential for significant total shareholder return. The company reported strong fourth-quarter and full-year 2025 financial results. Collegium announced a campaign with Paris Hilton for JORNAY PM. Collegium announced its acquisition of AZSTARYS® from Corium Therapeutics. Collegium announced participation in upcoming investor conferences.

Demand Seasonality affecting Collegium Pharmaceutical, Inc.’s stock price

Demand seasonality for Collegium Pharmaceutical's products is evident, particularly for its ADHD medication, Jornay PM. The company anticipates a strong "back-to-school" season and second half of the year for Jornay PM, leading to increased revenue guidance. The consistent growth in the pain portfolio throughout the year suggests a more stable demand profile.

Overview of Collegium Pharmaceutical, Inc.’s business

Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on improving the lives of individuals with serious medical conditions. The company operates in the pharmaceuticals sector, focusing on pain management and neuropsychiatry, particularly ADHD. Collegium develops, licenses, and acquires a portfolio of differentiated medications, including Jornay PM for ADHD, Belbuca for severe pain, Xtampza ER for moderate to severe pain, Nucynta ER/IR for severe and acute pain, and Symproic for opioid-induced constipation.

COLL’s Geographic footprint

Collegium Pharmaceutical, Inc. primarily commercializes its products in the United States and is headquartered in Stoughton, Massachusetts.

COLL Corporate Image Assessment

Collegium Pharmaceutical aims to maintain a positive reputation by focusing on responsible pain management and improving the lives of people with serious medical conditions. Collegium was dismissed from opioid-related litigation, which is a positive for its reputation. The company's products like Xtampza ER are designed with abuse-deterrent properties, which contributes positively to its reputation. The acquisition of Jornay PM and the agreement to acquire AZSTARYS® demonstrate a strategic diversification into neuropsychiatry, specifically ADHD. Collegium has presented new real-world data at conferences and published studies highlighting the benefits of its treatments.

Ownership

Institutional ownership dominates Collegium Pharmaceutical's ownership structure, with 274 institutional owners and shareholders holding a total of 35,926,959 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Eventide Asset Management, Llc. The largest individual shareholder is David Hirsch, owning 6,438,798 shares, representing 20.28% of the company. Insider ownership collectively holds low-single-digit percentages.

Price Chart

$35.30

0.97%
(1 month)

Top Shareholders

BlackRock, Inc.
16.13%
The Vanguard Group, Inc.
7.14%
Eventide Asset Management LLC
5.94%
Renaissance Technologies Holdings Corp.
5.12%
Fuller & Thaler Asset Management, Inc.
4.75%
Rubric Capital Management LP
4.73%
Janus Henderson Group Plc
4.58%
Principal Financial Group, Inc.
4.16%

Trade Ideas for COLL

Today

Sentiment for COLL

News
Social

Buzz Talk for COLL

Today

Social Media

FAQ

What is the current stock price of Collegium Pharmaceutical, Inc.?

As of the latest update, Collegium Pharmaceutical, Inc.'s stock is trading at $35.30 per share.

What’s happening with Collegium Pharmaceutical, Inc. stock today?

Today, Collegium Pharmaceutical, Inc. stock is down by -0.97%, possibly due to news.

What is the market sentiment around Collegium Pharmaceutical, Inc. stock?

Current sentiment around Collegium Pharmaceutical, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Collegium Pharmaceutical, Inc.'s stock price growing?

Over the past month, Collegium Pharmaceutical, Inc.'s stock price has decreased by -0.97%.

How can I buy Collegium Pharmaceutical, Inc. stock?

You can buy Collegium Pharmaceutical, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol COLL

Who are the major shareholders of Collegium Pharmaceutical, Inc. stock?

Major shareholders of Collegium Pharmaceutical, Inc. include institutions such as BlackRock, Inc. (16.13%), The Vanguard Group, Inc. (7.14%), Eventide Asset Management LLC (5.94%) ... , according to the latest filings.